Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer

Inclusion Criteria:

Patients with unresectable and chemotherapy resistant primary or recurrent carcinoma of colorectal, gastric or pancreatic origin
There must be pathologic evidence for malignancy with a soft tissue component of tumor evident on CT scan imaging or physical examination
Patient must be able to give informed consent
There must be an anticipated survival of at least 3 months
Performance status of 80-100 (Karnofsky performance status)
WBC count >= 3,000uL
Platelet count >= 100,000uL
Prothrombin time and partial thromboplastin time of <= 1.5 times the upper limit of normal
Women of childbearing potential must have a negative pregnancy test; women and men of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation; should a woman become pregnant during or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately
Patients with asymptomatic small volume bone disease not likely to require radiation therapy during the period of the vaccine trial will be eligible
Hemoglobin level > 9g/dL
There must be evidence of p53 over expression by immunohistochemistry with > 10% of cells within the tumor strongly positive
Patients with colorectal cancer will need to have failed to respond to 5-FU based therapy with oxaliplatin, irinotecan as well as epidermal growth factor receptor (EGFR) directed therapies (if appropriate); patients with gastric cancer will need to have progressed on standard first line chemotherapy or chemoradiotherapy and Herceptin based therapy (if appropriate); patients with pancreatic cancer who have failed to respond to at least 1 chemotherapy regimen

Exclusion Criteria:

Diagnosis which has been associated with immunodeficiency, including HIV
Prior radiation to more than 50% of all nodal groups
Concurrent use of corticosteroids
History of another malignancy, other than nonmelanoma skin cancer in the past 2 years
Recent major surgery
Serious intercurrent illness
Temperature >= 101F within 3 days prior to the initial injection
Pregnancy or lactation
Clinically evident brain metastasis
Autoimmune disease
HIV seropositivity or refusal to hear the results of the HIV test
Receipt of organ grafts
History of severe environmental allergies
History of severe neurological, cardiovascular, renal, hepatic, endocrine, respiratory, or bone marrow dysfunction requiring frequent re-evaluation, and management by a physician
Patients with a history of congestive heart failure or coronary artery disease which has not been resolved by bypass or stent
History of myopericarditis
Known family history of Li-Fraumeni syndrome
Allergy to egg proteins
Chemotherapy or radiation within the 4 weeks preceding enrollment